|
|
Volumn 2, Issue 11, 2014, Pages 1103-1112
|
|
IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model
a a a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
INTERLEUKIN 4;
MONOCLONAL ANTIBODY;
STAT5 PROTEIN;
TRASTUZUMAB;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
BIOSYNTHESIS;
DRUG EFFECTS;
ENZYME LINKED IMMUNOSORBENT ASSAY;
GENE EXPRESSION REGULATION;
GENETICS;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
MOUSE;
PHYSIOLOGY;
PROCEDURES;
REAL TIME POLYMERASE CHAIN REACTION;
TRANSGENIC MOUSE;
TUMOR MICROENVIRONMENT;
WESTERN BLOTTING;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BLOTTING, WESTERN;
ENZYME-LINKED IMMUNOSORBENT ASSAY;
GENE EXPRESSION REGULATION, NEOPLASTIC;
HUMANS;
IMMUNOTHERAPY;
INTERLEUKIN-4;
MICE;
MICE, TRANSGENIC;
REAL-TIME POLYMERASE CHAIN REACTION;
RECEPTOR, ERBB-2;
STAT5 TRANSCRIPTION FACTOR;
TRASTUZUMAB;
TUMOR MICROENVIRONMENT;
|
|
EID: 84991489680
PISSN: None
EISSN: 23266074
Source Type: Journal
DOI: 10.1158/2326-6066.CIR-14-0103 Document Type: Article |
|
Times cited : (16)
|
|
References (0)
|